Skip to Content


Active Substance: zaleplon
Common Name: zaleplon
ATC Code: N05CF03
Marketing Authorisation Holder: Meda AB
Active Substance: zaleplon
Status: Withdrawn
Authorisation Date: 1999-03-12
Therapeutic Area: Sleep Initiation and Maintenance Disorders
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Sonata is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.

The marketing authorisation for Sonata has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.